U.S. markets open in 3 hours 2 minutes

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
48.79+2.82 (+6.13%)
At close: 04:00PM EST
50.60 +1.81 (+3.71%)
After hours: 07:49PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close45.97
Bid0.00 x 1100
Ask0.00 x 2900
Day's Range46.61 - 50.74
52 Week Range27.77 - 80.00
Avg. Volume815,425
Market Cap3.438B
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-3.59
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est77.69
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BEAM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Beam Therapeutics Inc.
    Daily – Vickers Top Buyers & Sellers for 01/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    17 days agoArgus Research
View more
  • TipRanks

    Cathie Wood pours millions into these 2 stocks — this is what makes them attractive buys

    January has now been and gone and turned out to be a nice gift for investors. Battered by 2022’s bear, the tech-heavy Nasdaq, in particular, put in an excellent showing, seeing out the month ~11% into the green, in what amounted to its best start to a year since 2001. That signals the appetite for risk is on again and that will be good news for Cathie Wood, the ARK Investment CEO, whose investing style heavily favors disruptors - equities that are naturally positioned at the risky end of the sca

  • InvestorPlace

    7 CRISPR Stocks With the Best Long-Term Potential

    CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks

  • Simply Wall St.

    Shareholders in Beam Therapeutics (NASDAQ:BEAM) are in the red if they invested a year ago

    Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders should be happy to see the share price up 16% in the last month...